Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
September 16, 2022 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2022 16:05 ET
|
Annexon Biosciences
BRISBANE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
August 08, 2022 16:01 ET
|
Annexon Biosciences
Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts Anticipated throughout 2022 and 2023 Operating...
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
July 11, 2022 18:25 ET
|
Annexon Biosciences
BRISBANE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Announces $130 Million Private Placement Financing
July 08, 2022 07:00 ET
|
Annexon Biosciences
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease
June 07, 2022 06:30 ET
|
Annexon Biosciences
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month StudyRapid Improvement in Clinical...
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
June 02, 2022 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
June 01, 2022 07:30 ET
|
Annexon Biosciences
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET
|
Annexon Biosciences
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023...
Annexon Biosciences to Participate in Upcoming May Investor Conferences
May 05, 2022 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...